Free Newsletter
House votes to treat tobacco as a drug
If the U.S. House gets its way, the FDA soon may have even more power--to regulate tobacco as a drug. Reps voted overwhelmingly to charge the agency with overseeing the tobacco industry, in spite of a veto threat by President Bush. It's a move long sought by anti-smoking advocates, and one lobbied for, as you may recall, by ex-FDA chief David Kessler.
Under the bill the agency would be able to reduce the amount of addictive nicotine in cigarettes and smokeless tobacco--though not remove it altogether--plus ban various additives, such as candy and fruit flavorings designed to appeal to youngsters. And tobacco makers would have to disclose all the different additives in their products and hand over research into their effects.
In declaring its opposition, the White House said that the FDA is already overstretched as it is. But that didn't seem to bother frequent agency critic John Dingell, a vehement supporter of the measure. It's not clear as yet whether the Senate can come up with a veto-proof majority for the bill. Stay tuned; it's sure to cause lots of debate.
- read the Washington Post story
- see the article in the New York Times
Related Articles:
Tobacco used to create new cancer vaccine
WHO: Tobacco could kill one billion by 2100
Grassley, Dingell plan FDA renovation
Comments
"It's a move long sought by anti-smoking advocates..."
This article fails to mention that Philip Morris is in favor of FDA regulation.
Search FDA regulation on the philipmorrisusa(dot)com website and see for yourself.
Philip Morris thinks it would help them crush their competition.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





